NYSE:TAK • US8740602052
The current stock price of TAK is 18.12 USD. Today TAK is down by -0.49%. In the past month the price increased by 0.11%. In the past year, price increased by 20.72%.
ChartMill assigns a technical rating of 9 / 10 to TAK. When comparing the yearly performance of all stocks, TAK is one of the better performing stocks in the market, outperforming 83.43% of all stocks.
ChartMill assigns a fundamental rating of 5 / 10 to TAK. While TAK has a great profitability rating, there are quite some concerns on its financial health.
On January 30, 2026 TAK reported an EPS of 32.81 and a revenue of 1.19T. The company beat EPS expectations (90.61% surprise) and beat revenue expectations (0.21% surprise).
19 analysts have analysed TAK and the average price target is 18.18 USD. This implies a price increase of 0.31% is expected in the next year compared to the current price of 18.12.
For the next year, analysts expect an EPS growth of 74.57% and a revenue growth -1.2% for TAK
Over the last trailing twelve months TAK reported a non-GAAP Earnings per Share(EPS) of 0.23. The EPS decreased by -45.17% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 2.53% | ||
| ROA | 0.73% | ||
| ROE | 1.48% | ||
| Debt/Equity | 0.56 |
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 28.6 | 944.634B | ||
| JNJ | JOHNSON & JOHNSON | 20.86 | 587.317B | ||
| MRK | MERCK & CO. INC. | 22.45 | 289.492B | ||
| PFE | PFIZER INC | 9.14 | 154.439B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.47 | 122.453B | ||
| ZTS | ZOETIS INC | 16.92 | 50.862B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.04 | 26.518B | ||
| VTRS | VIATRIS INC | 5.57 | 16.212B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.29 | 11.768B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.508B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.528B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 4.81B | ||
| LGND | LIGAND PHARMACEUTICALS | 26.06 | 4.233B |
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the New York Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 47,455 full-time employees. The firm focuses on the main business areas of gastrointestinal diseases, rare diseases, plasma derivatives (immune diseases), oncology (cancer), and neuroscience (neuropsychiatric diseases). The firm focuses on three research and development areas: innovative biopharmaceuticals with the focus on gastrointestinal and inflammatory diseases, neuroscience, and oncology, plus plasma derivatives and vaccines. Most of the pharmaceuticals treat rare diseases in the focus disease areas and the plasma derivatives area. The firm operates in Japan, the United States, Europe, and China.
IPO: 1949-05-16
TAKEDA PHARMACEUTIC-SP ADR
4F, 2-1-1, Nihombashihon-cho
Chuo-Ku TOKYO-TO 103-8668 JP
CEO: Christophe Weber
Employees: 47455
Phone: 81332782111
Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 47,455 full-time employees. The firm focuses on the main business areas of gastrointestinal diseases, rare diseases, plasma derivatives (immune diseases), oncology (cancer), and neuroscience (neuropsychiatric diseases). The firm focuses on three research and development areas: innovative biopharmaceuticals with the focus on gastrointestinal and inflammatory diseases, neuroscience, and oncology, plus plasma derivatives and vaccines. Most of the pharmaceuticals treat rare diseases in the focus disease areas and the plasma derivatives area. The firm operates in Japan, the United States, Europe, and China.
The current stock price of TAK is 18.12 USD. The price decreased by -0.49% in the last trading session.
TAKEDA PHARMACEUTIC-SP ADR (TAK) has a dividend yield of 3.55%. The yearly dividend amount is currently 0.61.
TAK has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on TAK.
TAKEDA PHARMACEUTIC-SP ADR (TAK) has a market capitalization of 57.24B USD. This makes TAK a Large Cap stock.
The outstanding short interest for TAKEDA PHARMACEUTIC-SP ADR (TAK) is 0.21% of its float.